Episode 11: Obesity Week 2023: An Interview with Dr. Angela Fitch, President, Obesity Medicine Association

Patients are experiencing remarkable weight loss thanks to the new generation of GLP-1’s and the downstream health benefits may go well beyond diabetes. In spite of the dramatic results for patients, insurance plans have started to put up more barriers and are even denying the drugs on a more consistent basis. For this special Obesity Week 2023 episode, we interview Dr. Angela Fitch, President of the Obesity Medicine Association, a faculty member at Harvard Medical School and most recently a Co-Founder and Chief Medical Officer for knownwell, a new obesity-focused primary care company.

Show Notes:

Dr. Angela Fitch, President, OMA

Obesity Week

Obesity Medical Association

Dr. Fitch’s patient care center: Knownwell

Seeking treatment for obesity? Find a clinician here or here.

The Treat and Reduce Obesity Act of 2023

The drugs discussed in this episode:

• GLP-1 (Glucagon-like peptide-1)
• Wegovy (Semaglitude)
• Victoza (Liraglutide)

An article on the use of “bootlegged” Semaglitude: Demand Rising for 'Bootlegged' Weight-Loss Drug | MedPage Today

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.

Find us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.